Type 2 Diabetes Remission and What It Does to Chronic Pain

Two questions get run together in this field and deserve separating.

Can type 2 diabetes go into remission? Yes — and it has been demonstrated in randomised trials.

Does fixing the metabolic problem improve chronic pain? Often, in clinical experience, and for mechanistically sensible reasons — but that specific question has not been tested the way the remission question has.

This article gives the real numbers for the first, is honest about the second, and explains how to read the very high success rates that circulate in this space, including from clinicians who broadly share this view.

What the remission trials actually achieved

DiRECT — the Diabetes Remission Clinical Trial — randomised primary care practices in the UK. At 12 months, remission was achieved in 46% of intervention participants against 4% of controls.¹ Remission was defined rigorously: HbA1c below 6.5% after at least two months off all diabetes medication. Mean weight loss was 10 kg. At 12 months, 74% of intervention participants were taking no diabetes medication at all.

Virta Health’s continuous remote care model, using nutritional ketosis, reported at one year that 94% of patients on insulin had reduced or eliminated it, with average weight loss around 12%.² This was an open-label, non-randomised, controlled study — weaker evidence than DiRECT by design, but a large and carefully reported cohort.

Those are the anchor numbers. They are genuinely encouraging and they demolish the idea that type 2 diabetes is inevitably progressive.

How to read the higher figures you will encounter

You will hear substantially higher success rates quoted in this space — including figures in the range of 85 to 90% of patients achieving resolution within a few months.

I want to be direct about how to interpret those, because the honest framing serves you better than the impressive one.

Numbers like that come from clinical practice rather than from trials. Practice-reported outcomes differ from trial results in ways that systematically inflate them: the patients are self-selected and highly motivated, there is no randomised control group, “resolution” may be defined more loosely than DiRECT’s two-months-off-all-medication standard, and patients who disengage often are not counted.

None of that means such results are fabricated. Motivated patients in an intensive programme genuinely can outperform trial averages. But a practice figure that substantially exceeds the best published randomised evidence should be treated as a claim requiring audit, not as an established result — and that is true no matter who is saying it, including me.

The defensible statement is this: remission is achievable for a meaningful proportion of people with type 2 diabetes, trial evidence puts that proportion around 46% at 12 months under good conditions, and individual results vary considerably.

Why pain often improves before the weight does

This is the part patients find most surprising, and it is mechanistically the most interesting.

People frequently report reduced pain within weeks of a substantial dietary change — well before meaningful weight loss has occurred. That timing rules weight loss out as the main explanation and points to something faster.

Three plausible mechanisms operate on that timescale:

Inflammation falls quickly. Removing refined carbohydrate, added sugar and industrial seed oil reduces inflammatory signalling within days to weeks. A less inflamed nervous system is a less sensitive one.

Glucose variability settles. Large glucose swings are themselves a stressor on nerve tissue and on the endothelium. Flattening the curve removes a repeated insult.

Insulin comes down. Insulin influences sodium retention, sympathetic tone and vascular behaviour. Lowering it changes tissue conditions independently of fat mass.

The honest caveat: no randomised trial has compared metabolic intervention against usual care using chronic pain as the primary outcome. The mechanistic reasoning is sound and the clinical pattern is consistent, but this remains clinical observation rather than proven treatment. Individual results vary.

What this means practically

If you have both chronic pain and type 2 diabetes or pre-diabetes, they are not two unrelated problems that happen to share a patient. Treating them as one problem is a better bet than treating either alone — and the metabolic work is the part most likely to change the trajectory rather than the symptom.

Remission is also not a cure. It can be lost if the conditions that produced the disease return. That framing matters: it is a state you maintain, not a box you tick.

Frequently asked questions

Key takeaways

• Type 2 diabetes remission is real and trial-proven: 46% at 12 months in DiRECT versus 4% of controls.
• Virta’s cohort reported 94% of insulin users reducing or eliminating insulin at one year, in a non-randomised study.
• Practice-reported rates far above trial figures reflect self-selection and looser definitions — treat them as claims needing audit.
• Pain often improves within weeks, before weight loss, pointing to inflammation and insulin rather than mass.
• No trial has yet tested metabolic treatment with chronic pain as the primary outcome.

Medically reviewed by Gurpreet Singh Padda, MD — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication without consulting your physician. To be evaluated, request an appointment or call (314) 481-5000.

References

1. Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet. 2018;391(10120):541–551.
2. Hallberg SJ, McKenzie AL, Williams PT, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. Diabetes Therapy. 2018;9(2):583–612.
3. Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes & Endocrinology. 2019;7(5):344–355.
4. Feinman RD, Pogozelski WK, Astrup A, et al. Dietary carbohydrate restriction as the first approach in diabetes management. Nutrition. 2015;31(1):1–13.
5. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2–S15.

Dr. Gurpreet Singh Padda, MD, MBA, MHP